Helmy Eltoukhy is the Co-Chief Executive Officer of Guardant Health, where he has been a key leader since co-founding the company in 2013. His background is in biotechnology, and he earned a Ph.D. in Bioengineering from Stanford University. Before starting...

Helmy Eltoukhy is the Co-Chief Executive Officer of Guardant Health, where he has been a key leader since co-founding the company in 2013. His background is in biotechnology, and he earned a Ph.D. in Bioengineering from Stanford University. Before starting Guardant Health, Helmy worked at Illumina, a major player in genetic analysis. He played a significant role in developing innovative technologies for genetic sequencing, which helps improve cancer detection and treatment. He also co-founded Avantome, a company focused on semiconductor sequencing, which was later acquired by Illumina. In 2021, he was appointed Chairperson of the Board at Guardant Health, marking a new chapter in his career while continuing to lead the company's oncology division. Interestingly, Helmy waived his salary and bonuses for seven years to align his interests with the company's performance and focus on long-term growth. This commitment shows his dedication and belief in what Guardant Health is doing to change lives through advanced cancer diagnostics.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Guardant Health CEOs

G

Helmy Eltoukhy

Founder and Ex-CEO of Guardant Health

Education

Ph.D. in Electrical Engineering from Stanford University

Field of Expertise

Technology & Engineering - Engineering

Sector of Economy

Healthcare

Born

January 1, 1978 - 47 years ago

CEO of Guardant Health for

8 years 7 months (Jan 2013 - Aug 2021)

Previous Experience

Co-founder of Guardant Health

Rivals

Competitors/colleagues of Helmy Eltoukhy

V

Rebecca Chambers

CEO of Veracyte

2023 Compensation

Stock

$0.00

Salary

$510.00K

Bonus

$388.49K

Other

$3.00K

Total Holdings

$4.42M

Holdings

See how much did Helmy Eltoukhy make over time.

Helmy Eltoukhy holds significant stock in Guardant Health, reflecting his commitment to the company's future. In 2020, his total compensation was around $113.9 million, mostly from vested stock options due to the Founders’ Performance Awards he waived for several years....

Helmy Eltoukhy holds significant stock in Guardant Health, reflecting his commitment to the company's future. In 2020, his total compensation was around $113.9 million, mostly from vested stock options due to the Founders’ Performance Awards he waived for several years. By 2021, his compensation dramatically dropped to just $13,665 as he opted out from annual incentive plans, showing his focus on long-term vision over immediate gains. This was a sharp contrast to the previous year when he received substantial vested stock valued at $218.5 million. His approach is clear: align interests with the company's growth and success.

Mar 18, 2025

G

shares

GH @ $43.85

Total Stock Sold

$425.27M

GH

$425.27M

3,480,001 GH shares

What if they kept their stock?

If Helmy Eltoukhy didn't sell their stock, today they would have:
Extra GH3,480,001 shares worth $289.61M.
This is -31.9% and $135.66M less than what they got when they sold the stock.

Charitable Transactions

GH

121,353 shares

GH

Recent Charitable Transactions

GH

120,000 shares

GH

Dec 31, 2019

Charity

GH

1,353 shares

GH

Dec 31, 2019

Charity

Insider Trading

See recent insider trades of Helmy Eltoukhy.

GH

$2.44M

GH at $26.24/share

Mar 14, 2023

Purchase

GH

$10.01M

GH at $95.78/share

Nov 19, 2021

Purchase

GH

$1.30M

GH at $160.07/share

Apr 23, 2021

Sale

GH

$10.90M

GH at $150.68/share

Apr 20, 2021

Sale

GH

$40.62M

GH at $156.72/share

Apr 15, 2021

Sale

GH

$37.27M

GH at $155.52/share

Apr 12, 2021

Sale

GH

$35.11M

GH at $159.10/share

Apr 7, 2021

Sale

GH

$25.59M

GH at $159.03/share

Jan 22, 2021

Sale

GH

$79.76M

GH at $163.08/share

Jan 19, 2021

Sale

GH

$23.79M

GH at $158.57/share

Jan 15, 2021

Sale

Compensation History

See how much did Helmy Eltoukhy make over time.

In 2021, Helmy Eltoukhy's total compensation was notably low at $13,665, as he waived his salary and annual incentive payouts for a seven-year period. This decision was made to maintain focus on the long-term success of Guardant Health. Back in 2020, however, his total compensation peaked at $113.9 million, of which a significant part came from vested stock worth about $218 million from performance-based awards. This pattern highlights his strategy of investing in his company's growth rather than taking immediate financial rewards. Over the years, Helmy's compensation has reflected both his commitment to align his interests with those of the company and the trust he places in Guardant's mission to revolutionize cancer detection.

Year

2021

Total Compensation

$13.67K

Salary

$1.00

Board Justification

The compensation philosophy aims to attract, retain, and motivate talented individuals while linking pay to performance and aligning executive interests with those of stockholders.

Bonus

$0.00

Board Justification

Dr. Eltoukhy waived his opportunity to receive annual incentive opportunities or payouts under the annual incentive plan for seven years due to the Founders’ 2020 Performance Awards.

Other

$13.66K

Board Justification

This amount includes waived health insurance premiums and related tax reimbursements resulting from the salary waiver.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock grants were made to Dr. Eltoukhy in 2021 due to the waiver agreement.

Performance Metrics

Dr. Eltoukhy's compensation was not determined by performance metrics due to the waiver of compensation agreements.

Other Guardant Health CEOs

Here are other CEOs of Guardant Health

AmirAli Talasaz

Founder and CEO of Guardant Health

August 2021 - Present